OMCL Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.

Company profile

Randall Lipps
Fiscal year end
Industry (SIC)
Former names
IRS number

OMCL stock data



24 Feb 21
28 Feb 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Omnicell earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 489.92M 489.92M 489.92M 489.92M 489.92M 489.92M
Cash burn (monthly) 46.42M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 91.66M n/a n/a n/a n/a n/a
Cash remaining 398.26M n/a n/a n/a n/a n/a
Runway (months of cash) 8.6 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Feb 21 Randall A Lipps Common Stock Grant Aquire A No No 0 20,715 0 230,352
9 Feb 21 Randall A Lipps Common Stock Grant Aquire A No No 0 20,715 0 186,116
9 Feb 21 Dan S Johnston Common Stock Grant Aquire A No No 0 4,760 0 37,164
9 Feb 21 Dan S Johnston Common Stock Grant Aquire A No No 0 5,675 0 32,405
9 Feb 21 Scott Peter Seidelmann Common Stock Grant Aquire A No No 0 9,520 0 47,918
9 Feb 21 Scott Peter Seidelmann Common Stock Grant Aquire A No No 0 11,350 0 38,398
9 Feb 21 Peter J. Kuipers Common Stock Grant Aquire A No No 0 11,350 0 71,713
9 Feb 21 Peter J. Kuipers Common Stock Grant Aquire A No No 0 9,520 0 60,363
13F holders
Current Prev Q Change
Total holders 340 293 +16.0%
Opened positions 75 47 +59.6%
Closed positions 28 37 -24.3%
Increased positions 86 101 -14.9%
Reduced positions 135 100 +35.0%
13F shares
Current Prev Q Change
Total value 10.85B 3.16B +243.8%
Total shares 42.49M 42.31M +0.4%
Total puts 13.4K 32.4K -58.6%
Total calls 66K 41K +61.0%
Total put/call ratio 0.2 0.8 -74.3%
Largest owners
Shares Value Change
BLK Blackrock 6.66M $799.7M +2.7%
Vanguard 4.49M $539.18M +1.3%
Wellington Management 2.51M $301.2M -18.7%
Conestoga Capital Advisors 1.62M $194.12M +1.3%
CS Credit Suisse 1.36M $162.64M -20.5%
STT State Street 1.29M $154.46M -3.1%
BK Bank Of New York Mellon 1.16M $138.74M +26.4%
Geneva Capital Management 910.28K $109.25M +2.8%
ArrowMark Colorado 891.22K $106.96M -36.8%
Dimensional Fund Advisors 875.6K $105.09M -3.0%
Largest transactions
Shares Bought/sold Change
Clearbridge Advisors 826.12K +615.34K +291.9%
Wellington Management 2.51M -578.91K -18.7%
ArrowMark Colorado 891.22K -519.65K -36.8%
WFC Wells Fargo & Co. 721.71K +470.49K +187.3%
MCQEF Macquarie 483.68K +449.67K +1322.1%
NMR Nomura 443.76K +438.03K +7651.2%
SG Americas Securities 449.39K +410.35K +1051.2%
CS Credit Suisse 1.36M -350.18K -20.5%
JHG Janus Henderson 0 -255.08K EXIT
BK Bank Of New York Mellon 1.16M +241.68K +26.4%

Financial report summary

  • We face risks related to adverse public health epidemics, including the ongoing global COVID-19 pandemic, which had an adverse effect on and, depending on the severity and duration of the pandemic, could continue to adversely affect our business, financial condition, and results of operations.
  • Unfavorable economic and market conditions and a decreased demand in the capital equipment market could adversely affect our operating results.
  • We may fail to develop new solutions or enhance existing solutions to react to changes in technology and customer requirements in a timely and cost-effective manner, or our new or enhanced solutions may not achieve market acceptance.
  • We operate in highly competitive markets, and we may be unable to compete successfully.
  • We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position.
  • The transition to selling more products which include a software as a service or solution as a service subscription presents a number of risks.
  • Delays in installations of our medication management automation solutions or our more complex medication packaging systems could harm our competitive position, results of operations, and financial condition.
  • We are subject to laws, regulations, and other legal obligations related to privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations could harm our business.
  • If we experience a significant disruption in our information technology systems, breaches of data security, or cyber-attacks on our systems or solutions, our business could be adversely affected.
  • We may fail to realize the potential benefits of acquired businesses, including the 340B Link Business, which could negatively affect our business, financial condition, and operating results.
  • If goodwill or other intangible assets that we recorded in connection with the Aesynt, Ateb, InPharmics, and 340B Link Business acquisitions, or other prior acquisitions, become impaired, we could be required to take significant charges against earnings.
  • The healthcare industry is subject to legislative and regulatory changes, as well as financial constraints and consolidation, which could adversely affect the demand for our products and services.
  • Government regulation of the healthcare industry could reduce demand for our products, or substantially increase the cost to produce our products.
  • Our international operations may subject us to additional risks that can adversely affect our operating results.
  • Covenants in our A&R Credit Agreement restrict our business and operations in many ways, and if we do not effectively manage our compliance with these covenants, our financial conditions and results of operations could be adversely affected.
  • Our success is dependent on our ability to recruit and retain skilled and motivated personnel.
  • Our failure to protect our intellectual property rights could negatively affect our ability to compete.
  • If we are unable to maintain our relationships with group purchasing organizations (“GPOs”) or other similar organizations, we may have difficulty selling our products and services to customers represented by these organizations.
  • We depend on a limited number of suppliers for our products, and our business may suffer if we were required to change suppliers to obtain an adequate supply of components, equipment, and raw materials on a timely basis.
  • The United Kingdom’s withdrawal from the European Union (“Brexit”) could adversely affect us.
  • Our U.S. government lease agreements are subject to annual budget funding cycles and mandated unilateral changes, which may affect our ability to enter into such leases or to recognize revenues, and sell receivables based on these leases.
  • If we fail to manage our inventory properly, our revenue, gross margin, and profitability could suffer.
  • Intellectual property claims against us could harm our competitive position, results of operations, and financial condition.
  • Product liability claims against us could harm our competitive position, results of operations, and financial condition.
  • We are dependent on technologies provided by third-party vendors, the loss of which could negatively and materially affect our ability to market, sell, or distribute our products.
  • The market price of our common stock may continue to be highly volatile.
  • Our quarterly operating results may fluctuate and may cause our stock price to decline.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or harm our business, financial condition, and results of operations.
  • Certain provisions in our charter documents and under Delaware law may delay or prevent an acquisition of us and limit our stockholders’ ability to obtain a favorable judicial forum for certain disputes.
  • Conversion of the Notes may dilute the ownership interest of our stockholders, depress the price of our common stock or, if the conditional conversion feature of the Notes is triggered, adversely affect our financial condition and operating results.
  • The accounting method for convertible debt securities that may be settled in cash, such as the Notes, could have a material effect on our reported financial results.
  • The convertible note hedge and warrant transactions may affect the value of our common stock.
  • Changes in our tax rates, exposure to additional tax liabilities, or the adoption of new tax legislation could adversely affect our business and financial condition.
  • Catastrophic events may disrupt our business and harm our operating results.
  • Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could cause our stock price to decline.
Management Discussion
  • Product revenues represented 71% and 74% of total revenues for the years ended December 31, 2020 and 2019, respectively. Product revenues decreased by $23.6 million, primarily due to the impact of the COVID-19 pandemic as health systems were focusing resources on COVID-19 essential activities during the second and third quarters of 2020.
  • Services and other revenues represented 29% and 26% of total revenues for the years ended December 31, 2020 and 2019, respectively. Services and other revenues include revenues from technical services, SaaS, subscription software, and technology-enabled services, and other services. Services and other revenues increased by $18.8 million, primarily due to revenues of $10.2 million from the newly-acquired 340B Link Business, as well as continued growth in our installed customer base.
  • Our international sales represented 11% and 10% of total revenues for the years ended December 31, 2020 and 2019, respectively, and are expected to be affected by foreign currency exchange rate fluctuations. We are unable to predict the extent to which revenues in future periods will be impacted by changes in foreign currency exchange rates.
Content analysis
H.S. sophomore Avg
New words: abreast, accretion, agency, amplify, Apothecary, argument, ascertaining, attrition, BD, belonging, bench, biggest, bribery, BW, CareScheduler, carryback, certainty, characteristic, circumstance, clarifying, coaching, collaboration, confidence, confident, consecutive, correlated, Corrupt, corruption, coupon, creditor, curriculum, deep, DEI, disburse, disbursed, discrimination, downloaded, EBITDA, EnlivenHealth, entirety, epidemic, ESAT, ESG, ethically, expropriation, feature, feedback, foregoing, forfeited, Forfeiture, forum, fractional, fullest, fundamental, Glint, gradual, GSA, gym, healthy, heightening, hoc, identical, IFF, imputed, indenture, insignificant, insolvency, intuitive, issuable, journey, landscape, learning, lieu, lifestyle, main, mental, mission, navigate, nonlease, onset, Organisation, Orientation, outreach, pandemic, payroll, Pharmacotherapy, philosophy, Plano, play, proceeding, prohibited, protocol, PSGH, pursuit, redemption, reinventing, robust, rulemaking, satisfaction, score, secondary, segregated, seller, semiannually, Shield, sinking, social, sooner, split, strike, strong, sweep, talent, Teladoc, Township, transparency, trustee, turnover, unfair, uninsured, unmet, unsecured, unusual, unwinding, vaccination, vaccine, viability
Removed: absorb, accredit, accredited, accuflex, add, adding, adjust, aesthetic, Affordable, AG, alike, alleged, Amerinet, Amortizing, Ann, approve, ARxIUM, attributable, bad, battery, Beijing, borrowed, Brewster, BriteSmile, cartfill, CenterTM, Centra, centralized, Cerner, characterized, closed, commerce, commonly, complementary, contingency, correct, Covidien, creating, decentralized, deem, delaying, demanding, Deployment, deposit, desire, detention, DIH, discouraging, discover, discovered, dispense, disrupted, disrupting, dissatisfied, doubtful, educating, elevate, eliminate, eliminating, enhancing, erode, Excellence, excessive, extremely, formal, frequent, Guardian, harmonize, heavily, hiring, hybrid, implementing, imprisonment, incumbent, instability, Intalere, integrity, intelligent, interfaced, interfacing, interoperate, introduced, inventorship, isolation, join, Jonathan, kls, KUKA, lack, Lancing, Lastly, legacy, licensure, managerial, Manchac, match, McIntire, McKesson, MedCarousel, membership, mindshare, minimizing, Nashville, newly, Ngo, Nhat, nurse, OmniCenter, oncology, OnDemand, outsourced, outsourcing, pace, penetration, Pittman, positioning, PPACA, practiced, preparing, preventing, prioritized, proposal, protecting, quantity, ramp, rapid, rebalanced, recording, recruiting, referenda, released, releasing, rent, repeal, replacing, replicate, reserve, restructure, Richmond, robopharma, rollout, Ruth, rx, SafetyStock, Science, Secretary, securing, sentiment, server, Shaw, shelf, show, simple, SinglePointe, Slovenia, solve, stabilize, Steuerungstechnik, stoppage, stratified, submitted, supplied, suremed, sustaining, Swisslog, symbiotic, Synergy, Tennessee, thirty, transmitted, Trieste, unclear, undetected, unemployment, uniformity, uniquely, unlawful, utilized, VBM, vehicle, Veteran, Virginia, Warner, WebsterCare, Willach, Yuyama